VivoSeq
Other

Monoclonal

0

Pipeline Programs

10

Active Trials

14

Companies Involved

Monoclonal is an early-stage landscape with 0 programs across 14 companies. The most active players are Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Brii Biosciences Limited, Genor Biopharma Co., Ltd..

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

7/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

75

clinical trials

Completed42 · 56%
Unknown status17 · 23%
Recruiting5 · 7%
Active, not recruiting3 · 4%
Terminated3 · 4%
Withdrawn2 · 3%
Other3 · 4%

Trial Activity

75 trials

Safety of RSV Preventive Monoclonal Antibody
Recruiting··Phase 4·NCT07158814·524 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)